HETEROAROMATIC MODULATORS OF THE RETINOID-RELATED ORPHAN RECEPTOR GAMMAThe present invention relates to a compound according to general formula (I) wherein X represents N or CH; R1 is -CN, (C1-C6)alkyl, (C3-C7)cycloalkyl, (3-7 membered)heterocycloalkyl, (5-6 membered)heteroaryl, (C3-C7)cycloalkyl(C1-C4)alkyl, (3-7 membered)heterocycloalkyl-(C1-C4)alkyl or (5-6 membered)heteroaryl- (C1-C4)alkyl; R2 is halogen, cyano, (C1-C4)alkyl or (C3-C7)cycloalkyl; R3 is halogen, cyano, (C1-C4)alkyl, (C1-C4)haloalkyl or (C3-C7)cycloalkyl; R4 is (C1-C4)alkyl or (C1-C4)haloalkyl; R5 is (C1-C6)alkyl, (C3-C7)cycloalkyl, (C1-C6)alkyl-(C3-C7)cycloalkyl, (C3-C7)cycloalkyl-(C1-C6)alkyl, (3-7 membered)heterocycloalkyl, phenyl, (5-6 membered)heteroaryl or -ORa. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compoundsand to intermediates for preparation of said compounds.According to the compound for leading to formula (i)wherein x indicates n or ch；r1selected from the group being made up of :-cn, (c1–c6) alkyl, (c3–c7) naphthenic base, (3-7 member) heterocyclylalkyl, (5-6 member) heteroaryl, (c3–c7) naphthenic base (c1–c4) alkyl, (3-7 member) heterocyclylalkyl-(c1–c4) alkyl and (5-6 member) heteroaryl-(c1– c4) alkyl, wherein (the c1–c6) alkyl, (c3–c7) naphthenic base, (3-7 member) heterocyclylalkyl, (5-6 member) heteroaryl, (c3–c7) naphthenic base (c1–c4) alkyl, (3-7 member) heterocyclylalkyl-(c1–c4) alkyl and (5-6 member) heteroaryl-(c1–c4) alkyl is optionally it is independently selected by one or more from r6substituent group replace；r2selected from the group being made up of: halogen, cyano, (c1–c4) alkyl and (c3–c7) naphthenic base, wherein (the c1–c4) alkane base and (c3–c7) naphthenic base is optionally independently selected by one or more from-oh and the substituent group of halogen replaces；r3selected from the group being made up of: halogen, cyano, (c1–c4) alkyl, (c1–c4) halogenated alkyl and (c3–c7) naphthenic base；r4selected from the group being made up of: (c1–c4) alkyl and (c1–c4) halogenated alkyl；r5selected from the group being made up of: (c1–c6) alkyl, (c3–c7) naphthenic base, (c1–c6) alkyl-(c3–c7) naphthenic base, (c3– c7) naphthenic base-(c1–c6) alkyl, (3-7 member) heterocyclylalkyl, phenyl, (5-6 member) heteroaryl and-ora；wherein (the c1–c6) alkyl, (c3–c7) naphthenic base, (c1–c6) alkyl-(c3–c7) naphthenic base, (c3–c7) naphthenic base-(c1–c6) alkyl, (3-7 member) be miscellaneous naphthenic base, phenyl, (5-6 member) heteroaryl and-oraoptionally it is independently selected by one or more from r7substituent group replace；r6indicate the group being made up of :-oh ,-cn, halogen ,=o ,-s (o)2rb、-nrcrd、-nrcc(o)rd、-c(o) nrcrd、-s(o)2nrcrd、-nrcs(o)2rb、-orb、-c(o)rb、(c1–c4) alkyl, hydroxyl (c1–c4) alkyl, halogenated (c1–c4) alkyl, (c3–c7) naphthenic base, (3-7 member) heterocyclylalkyl and (5-6 member) heteroaryl；r7indicate the group being made up of :-oh ,-cn, halogen, (c1–c4) alkyl, (c3-c7) naphthenic base and (c1–c6) alkyl- (c3–c7) naphthenic base-；raindicate (c1–c6) alkyl, (c3–c7) naphthenic base, (c1–c6) alkyl-(c3–c7) naphthenic base-or (c3–c7)-naphthenic base (c1–c6) alkyl；rbindicate (c1–c6) alkyl or (c3–c7) naphthenic base；rcand rdeach independently represent h, (c1–c6) alkyl or (c3–c7) naphthenic base；or its pharmaceutically acceptable salt, hydrate or solvate.
레티노이드-관련 희귀 수용체 감마의 신규한 헤테로방향족 조절제본 발명은 하기 일반식 (I)에 따른 화합물에 관한 것이다:[이미지] 식 중, X는 N 또는 CH이고; R1은 -CN, (C1-C6)알킬, (C3-C7)사이클로알킬, (3-7원)헤테로사이클로알킬, (5-6원)헤테로아릴, (C3-C7)사이클로알킬(C1-C4)알킬, (3-7원)헤테로사이클로알킬-(C1-C4)알킬 또는 (5-6원)헤테로아릴-(C1-C4)알킬이며; R2는 할로겐, 사이아노, (C1-C4)알킬 또는 (C3-C7)사이클로알킬이고; R3은 할로겐, 사이아노, (C1-C4)알킬, (C1-C4)할로알킬 또는 (C3-C7)사이클로알킬이고; R4는 (C1-C4)알킬 또는 (C1-C4)할로알킬이며; R5는 (C1-C6)알킬, (C3-C7)사이클로알킬, (C1-C6)알킬-(C3-C7)사이클로알킬, (C3-C7)사이클로알킬-(C1-C6)알킬, (3-7원)헤테로사이클로알킬, 페닐, (5-6원)헤테로아릴 또는 -ORa이다. 본 발명은 또한 요법에 사용하기 위한 상기 화합물, 상기 화합물을 포함하는 약제학적 조성물 및 상기 화합물의 제조용의 중간체에 관한 것이다.하기 일반식 (I)에 따른 화합물, 또는 이의 약제학적으로 허용 가능한 염, 수화물 또는 용매화물:[이미지]식 중, X는 N 또는 CH이고;R1은 -CN, (C1-C6)알킬, (C3-C7)사이클로알킬, (3-7원)헤테로사이클로알킬, (5-6원)헤테로아릴, (C3-C7)사이클로알킬(C1-C4)알킬, (3-7원)헤테로사이클로알킬-(C1-C4)알킬 및 (5-6원)헤테로아릴-(C1-C4)알킬로 이루어진 군으로부터 선택되되, 상기 (C1-C6)알킬, (C3-C7)사이클로알킬, (3-7원)헤테로사이클로알킬, (5-6-원)헤테로아릴, (C3-C7)사이클로알킬(C1-C4)알킬, (3-7원)헤테로사이클로알킬-(C1-C4)알킬 및 (5-6원)헤테로아릴-(C1-C4)알킬은 R6으로부터 독립적으로 선택된 1개 이상의 치환기로 선택적으로 치환되며;R2는 할로겐, 사이아노, (C1-C4)알킬 및 (C3-C7)사이클로알킬로 이루어진 군으로부터 선택되되, 상기 (C1-C4)알킬 및 (C3-C7)사이클로알킬은 -OH 및 할로겐으로부터 독립적으로 선택된 1개 이상의 치환기로 선택적으로 치환되고;R3은 할로겐, 사이아노, (C1-C4)알킬, (C1-C4)할로알킬 및 (C3-C7)사이클로알킬로 이루어진 군으로부터 선택되며;R4는 (C1-C4)알킬 및 (C1-C4)할로알킬로 이루어진 군으로부터 선택되고;R5는 (C1-C6)알킬, (C3-C7)사이클로알킬, (C1-C6)알킬-(C3-C7)사이클로알킬, (C3-C7)사이클로알킬-(C1-C6)알킬, (3-7원)헤테로사이클로알킬, 페닐, (5-6원)헤테로아릴 및 -ORa로 이루어진 군으로부터 선택되되; 상기 (C1-C6)알킬, (C3-C7)사이클로알킬, (C1-C6)알킬-(C3-C7)사이클로알킬, (C3-C7)사이클로알킬-(C1-C6)알킬, (3-7원)헤테로사이클로알킬, 페닐, (5-6원)헤테로아릴 및 -ORa는 R7로부터 독립적으로 선택된 1개 이상의 치환기로 선택적으로 치환되며;R6은 -OH, -CN, 할로겐, =O, -S(O)2Rb, -NRcRd, -NRcC(O)Rd, -C(O)NRcRd, -S(O)2NRcRd, -NRcS(O)2Rb, -ORb, -C(O)Rb, (C1-C4)알킬, 하이드록시(C1-C4)알킬, 할로(C1-C4)알킬, (C3-C7)사이클로알킬, (3-7원)헤테로사이클로알킬 및 (5-6원)헤테로아릴로 이루어진 군을 나타내고;R7은 -OH, -CN, 할로겐, (C1-C4)알킬, (C3-C7)사이클로알킬 및 (C1-C6)알킬-(C3 - C7)사이클로알킬-로 이루어진 군을 나타내며;Ra는 (C1-C6)알킬, (C3 - C7)사이클로알킬, (C1-C6)알킬-(C3 - C7)사이클로알킬- 또는 (C3 - C7)-사이클로알킬(C1-C6)알킬을 나타내고;Rb는 (C1-C6)알킬 또는 (C3 - C7)사이클로알킬을 나타내며;Rc 및 Rd는 각각 독립적으로 H, (C1-C6)알킬 또는 (C3 - C7)사이클로알킬을 나타낸다.